Biogen says it will not give up on Alzheimer’s after failed trials

Biogen Inc. executives sought on Wednesday to ease investors’ concerns over the recent failure of one of the company’s investigational Alzheimer's drugs.

During an earnings call with analysts, head of research and development Michael Ehlers said the biotech giant BIIB, +0.28% planned to continue its pursuit of Alzheimer’s drugs, but would reduce its risk by focusing on diversifying its pipeline.